Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We are very proud to initiate this partnership with one of the top leaders in the pharma space, pairing our strong commitment and ambition cell and gene therapy, AstraZeneca, because we have been very much impressed by the long term strategy in this space |
| Backed by a strong commitment and development already made paving the way powered by top leadership in this arena |
| And as also you can see the safety quite good at this dose level as well |
| So we definitely have a significant vested interest Allogene success, just remembering upto to $410 million in development and sales milestones for CD- 19 through our agreement with the survey and up to $2.8 billion in development and sales milestones |
| And I hope that to the company is going to have like a very strong end of '23 and '24 and '25 and '26 |
| Within the collaboration, we will leverage our cutting edge innovation and best-in-class manufacturing capability |
| My question is also as it relates to the ASH abstracts really impressive results UCART20x22 program |
| At Cellectis, we strongly believe that our product candidates, our technologies and our in-house manufacturing capabilities will lead us and our partners to a paradigm shift for patient with hard to treat cancer, positioning us at the forefront of this promising medical and scientific field |
| It's been a pleasure to prepare this together, and I would like very warmly thank all the analysts that have been following the covenants supporting in watching what we're doing is very valuable |
| During this past third quarter Cellectis innovation key excelled in releasing disruptive preclinical data on gene editing of stem cell gene therapy for an immunological disease |
| We're very excited to get to work with AstraZeneca to leverage our capabilities and build the next-generation of genomic medicines to address areas of high unmet patient need together |
| So I think in the setting of 19 failures on having two CRs, is great is great news at this dose level |
| Post out this call, I would like to reiterate how excited we are about a strategic collaboration with AstraZeneca and how much confident we are about the continued progress of our three ongoing clinical trials in as well as our continued development of our pre-clinical program |
| UCART22, P2 was administered after fludarabine, cyclophosphamide, and alemtuzumab (FCA) lymphodepletion and was well tolerated |
| It's a very ambitious proposal to develop novel cell and gene therapies across oncology, immunology and rare diseases |
| We strongly believe that together since AstraZeneca, that next generation of genomic medicine will be developed under our collaboration will revolutionize medicine across a number of therapeutic areas in the years to come |
| Later, on our proprietary power base editing technology and multi armored allogenic CAR-T cell targeting MUC1 for triple negative breast cancer, demonstrating one more time to spend and the power of our gene-editing platform and to develop next-generation cell and gene therapies for patients with unmet medical need |
| In addition, our focus on maintaining an efficient corporate infrastructure should also enable more limited growth in G&A expense |
| The company believes that we have sufficient resources to continue operating for at least 12 months following the consolidated financial statements' publication |
| It's interesting to look for good duration of response in these patients |
| Thank you, and thanks for the update |
| And today, I think that will probably, the best on the planet to do allogenic CAR-T, as Mark said, come at our poster session at at ASH, watch the expansion of the cells, even a super low doses |
| The quality, the reproducibility of manufacturing is one of the game changer in the success of these therapies, which is why we have fully internalized manufacturing |
| Andre Choulika Yes, hi, nice events that and thank you very much for the nice question because I think that the manufacturing that tottaly makes a huge difference |
| Lastly, our AMELI-01 study evaluating UCART123 in patients with relapsed or refractory acute myeloid leukemia continues to progress and enroll patients in the FCA 2 dose regimen are |
| Thanks for all the questions |
| Thank you so much |
| Thank you so much |
| Thank you very much |
| So that's where we're continuing |
| Statement |
|---|
| They failed multi-agent chemo in and they also failed blinatumomab or inotuzumab and venetoclax |
| The net loss attributable to shareholders of Cellectis was $58 million were $1.7 per share |
| This was a patient who was again, as outlined in the abstract, was super heavily pretreated, they failed alo transplant, they failed prior octalagus CAR-T |
| The adjusted net loss attributable to shareholders of Cellectis, which excludes non-cash stock based compensation expenses, was $57 million, were $1.05 per share in the first nine month period of 2023 compared to a loss of $72 million or $1.58 per share in the first nine months of 2022 |
| So like this will continue to control strictly cash burn within these difficult market environment |
| These downward impacts on the net loss were partially offset by a decrease of $1.2 million of revenues and other income |
Please consider a small donation if you think this website provides you with relevant information